Vesicant drugs are medications capable of causing blisters, tissue destruction, and potentially deep wounds if they leak out of a vein and into surrounding tissue during intravenous (IV) infusion. The term comes from the Latin word for blister, and these drugs sit at the top of a severity scale: medications are classified as vesicants, irritants, or non-vesicants based on how much damage they can cause if something goes wrong during delivery. While many people encounter the term in the context of chemotherapy, a surprisingly wide range of common hospital medications also qualify as vesicants.
How Vesicants Damage Tissue
When an IV line slips or a vein wall becomes compromised, fluid can escape into the tissue around the injection site. This event is called extravasation. For most drugs, this causes mild swelling and discomfort. For vesicants, the consequences are far more serious.
Vesicant drugs damage tissue through two main pathways. Some drugs, particularly certain chemotherapy agents, are absorbed by local cells and bind directly to DNA or other critical structures inside those cells, killing them. When those cells die and break apart, they release the drug back into the surrounding tissue, where it gets taken up by neighboring cells and kills them too. This chain reaction is what makes these injuries so dangerous: the damage keeps spreading even after the infusion has stopped, impairing healing and sometimes causing progressive, chronic tissue injury that worsens over days or weeks.
Other vesicants cause damage through different mechanisms, such as extreme acidity, alkalinity, or concentration that chemically burns tissue on contact. These injuries tend to be more contained because the drug doesn’t bind to DNA and can be metabolized and cleared by the body more quickly.
Chemotherapy Vesicants
Chemotherapy drugs are the most well-known vesicants, and they’re grouped into several major classes. Anthracyclines, which include doxorubicin, daunorubicin, epirubicin, and idarubicin, are among the most potent. These are DNA-binding agents, meaning they trigger the chain-reaction cell death described above. Alkylating agents like nitrogen mustard work similarly.
Vinca alkaloids (vinblastine, vincristine, vinorelbine, and vindesine) are another important group. These drugs bind to structures called microtubules inside cells rather than DNA, and they require a different management approach if extravasation occurs. Taxanes, including docetaxel and paclitaxel, and antitumor antibiotics like dactinomycin and mitomycin-C round out the major categories.
The distinction between DNA-binding and non-DNA-binding vesicants matters clinically because it determines how the injury behaves and which antidote or first-aid measure is appropriate.
Non-Chemotherapy Vesicants
Many people are surprised to learn that common hospital drugs, not just chemotherapy, carry vesicant risk. The Infusion Nurses Society maintains a classification system that divides non-chemotherapy vesicants into two tiers based on how well-documented the tissue damage risk is.
The highest-risk group includes calcium chloride, calcium gluconate, concentrated dextrose solutions (10% and above), mannitol at 20% or higher, concentrated sodium chloride (3% and above), sodium bicarbonate, phenytoin (an anti-seizure medication), promethazine (an anti-nausea drug), and the vasopressors phenylephrine and vasopressin. Certain antibiotics, including nafcillin, also make this list, along with IV contrast dye.
A second tier of drugs carries vesicant potential with fewer published cases but enough concern to warrant caution. This includes several vasopressors used in critical care: dopamine, dobutamine, epinephrine, and norepinephrine. The antibiotic vancomycin, the antiviral acyclovir, the heart rhythm drug amiodarone, potassium solutions above 60 mEq/L, and parenteral nutrition formulas exceeding 900 mOsm/L also fall into this category.
What many of these non-chemotherapy vesicants share is extreme pH or very high concentration. Solutions with osmolarity above 600 mOsm/L are associated with tissue symptoms when they leak, and those above 800 mOsm/L generally require delivery through a central line rather than a standard peripheral IV.
What Extravasation Looks and Feels Like
Early signs of a vesicant leak are easy to confuse with a minor irritation. Pain, redness, a burning sensation, itching, or swelling at the IV site are typically the first things you’d notice. At this stage, the symptoms look identical to what a less dangerous irritant drug might cause.
What separates a vesicant injury is what happens next. Over hours to days, the redness intensifies, the skin may change color or develop a mottled appearance, and blisters can form. Blistering indicates at least a partial-thickness skin injury. The area may become firm and hard to the touch.
In more severe cases, a firm, hardened area progresses to a dry, dark scab (eschar) within one to two weeks. That scab eventually falls away to reveal an ulcer underneath. Full-thickness skin damage shows up as a white, non-blanching area where blood flow has been completely cut off. In the worst outcomes, the injury can require surgical intervention and, in extremely rare cases, has been fatal.
One of the most important things to understand is the timeline. Ulceration often doesn’t become visible until one to two weeks after the injury. With DNA-binding chemotherapy agents, the damage can continue to expand during that window because of the chain-reaction mechanism. This delayed progression means an extravasation that initially looks minor can turn serious.
Why Central Lines Are Preferred
Because the consequences of a vesicant leak can be severe, guidelines from the Infusion Nurses Society recommend that vesicant drugs be given through central venous access devices whenever possible. These are catheters whose tip sits in a large central vein near the heart, where blood flow is high enough to rapidly dilute the drug. This dramatically reduces the risk of tissue damage compared to a standard IV in the hand or arm.
Midline catheters, which terminate in smaller veins before reaching the central circulation, are specifically recommended against for continuous vesicant therapy. The same applies to parenteral nutrition formulas above 900 mOsm/L and any infusion with extreme pH or osmolarity. When peripheral IVs must be used for vesicants, the infusion site needs close, frequent monitoring throughout delivery.
How Extravasation Injuries Are Managed
If a vesicant leak is suspected, the infusion is stopped immediately and as much of the drug as possible is aspirated back through the catheter before it’s removed. What happens next depends on which drug leaked.
For anthracycline chemotherapy agents, the specific antidote is dexrazoxane. For alkylating agents like nitrogen mustard, sodium thiosulfate is used. Vinca alkaloids and taxanes are treated with hyaluronidase, an enzyme that helps break down tissue barriers and disperse the leaked drug so it can be absorbed and cleared.
Temperature also matters, and the correct choice depends on the drug. Cold compresses are recommended for anthracyclines, alkylating agents, antimetabolites, and taxanes when hyaluronidase is not being given. Cold slows cellular uptake of the drug, limiting how much tissue is exposed. Warm compresses are used for vinca alkaloids, etoposide, oxaliplatin, and taxanes when hyaluronidase is being administered, because warmth helps the enzyme work and promotes dispersion and absorption of the leaked drug.
Getting this warm-versus-cold distinction wrong can worsen the injury, which is one reason extravasation protocols are carefully standardized in hospitals. For many non-chemotherapy vesicants, no specific antidote exists, and management focuses on limiting spread, elevating the affected limb, and monitoring for tissue breakdown over the following days and weeks.
Who Faces Higher Risk
Certain patients are more vulnerable to extravasation and its consequences. People with fragile or small veins, including elderly patients and those who have undergone multiple rounds of chemotherapy, are at greater risk because their veins are more likely to be damaged or difficult to access. Patients who are sedated, unconscious, or unable to communicate pain may not report early symptoms, allowing the leak to continue longer before it’s caught. People with poor circulation, diabetes, or conditions affecting skin healing face worse outcomes if an injury does occur, because the body’s ability to repair the damage is already compromised.
Infants and young children also present elevated risk due to their small vein size and inability to describe discomfort. In all of these populations, the use of central venous access and vigilant monitoring during infusion becomes especially important.